HIV/TB-MR patients on a short course of multidrug-resistant tuberculosis

This title is printed to order. This book may have been self-published. If so, we cannot guarantee the quality of the content. In the main most books will have gone through the editing process however some may not. We therefore suggest that you be aware of this before ordering this book. If in doubt check either the author or publisher’s details as we are unable to accept any returns unless they are faulty. Please contact us if you have any questions.

A retrospective descriptive study was conducted in patients with MDR-TB in CAT, Cocody and Treichville Pneumo-Physiology Departments, from November 2013 to December 2015. Sputum from included patients was cultured monthly for 9 months. Out of 132 patients put on a short 9-month regimen, 22 (16.66%) were HIV infected including 6 cases of relapse and 4 lost to follow-up. At the consolidation phase of the short course of MDR-TB, cultures were negative for 14/18 (77.77%) and positive for 4/18 (22.22%). The D516V mutation in the rpoB gene was the most frequent among cured patients with 42.85%. One failure was observed in a patient infected with a double mutated strain (L511P, S522T). Among the failures, 2 patients were XDR. The estimated Od ratio according to rpoB gene mutation type and clinical category was 0.81 95% CI [0.13;20.57] and 0.27 95% CI [0.002; 2.82], respectively. The type of rpoB mutation and clinical category did not influence the treatment outcome of HIV/TBMR co-infected patients.